capecitabine / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

157 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
capecitabine / Generic mfg.
jRCTs031220572: Phase II study of CapeOX + nivolumab therapy for early recurrent gastric cancer

Recruiting
2
92
Japan
capecitabine - Generic mfg., Opdivo (nivolumab) - Ono Pharma, BMS, oxaliplatin - Generic mfg.
St. Marianna University Hospital, ONO PHARMACEUTICALO CO., LTD., Bristol-Myers Squibb Company
Early relapsed gastric cancer
 
 
RC48-C022, CTR20233553: A phase II clinical study to evaluate the efficacy and safety of injectable vedicitumab plus toripalimab with or without chemotherapy (capecitabine + oxaliplatin) versus chemotherapy for the perioperative treatment of resectable locally advanced gastric/g

Recruiting
2
90
China
Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, capecitabine - Generic mfg., oxaliplatin - Generic mfg.
Remegen Biopharmaceutical (Yantai) Co., Ltd
HER2-expressing resectable locally advanced gastric/gastroesophageal junction adenocarcinoma
 
 
2013-001203-36: Clinical trial to assess wether Lapatinib in association with Capecitabine and Radiation performs better than Capecitabine and Radiation in patients with localized rectal cancer Ensaio clínico para avaliar se a associação de Lapatinib com Capecitabina e Radioterapia é melhor do que Capecitabina e Radioterapia em doentes com cancro do recto localizado

Ongoing
2
80
Europe
Film-coated tablet, Tyverb
Instituto Português de Oncologia do Porto Francisco Gentil, EPE, GlaxoSmithKline, IPO Porto FG, EPE
Rectal cancer stage II Rectal cancer stage III Cancro do Reto, estádio II Cancro do Reto, estádio III, Rectal Cancer Cancro do Reto, Diseases [C] - Cancer [C04]
 
 
2010-022793-14: A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate the efficacy and safety of masitinib in combination with 5-fluorouracil (5-FU) or capecitabine, or masitinib in combination with irinotecan, or masitinib in combination with irinotecan, 5-fluorouracil (5-FU) and folinic acid (FOLFIRI protocol), as second line chemotherapy in patients with gastric or gastro-oesophageal junction metastatic adenocarcinoma.

Not yet recruiting
2
57
Europe
masitinib, Irinotecan, AB1010, Film-coated tablet, Solution for infusion, Irinotecan/Campto®/Camptosar®
AB Science
gastric or gastro-oesophageal junction metastatic adenocarcinoma
 
 
2004-000665-35: Study to assess the efficacy and safety of oral vinorelbine in combination with capecitabine in patients suffering from breast cancer previously treated with other chemotherapies (anthracyclines, and taxanes) Estudio para evaluar la eficacia y seguridad de vinorelbina oral en combinación con capecitabina en pacientes con cáncer de mama previamente tratadas on otras quimioterapias (antraciclinas y taxanos)

Ongoing
2
15
Europe
Navelbine Cápsulas Blandas, Xeloda, Not applicable, Navelbine Capsulas blandas, Xeloda, Navelbine Capsulas blandas, Xeloda
Pierre Fabre Medicament, Pierre Fabre Medicament
Treatment in metastatic breast cancer women previously treated with anthracyclines and taxanes
 
 
2017-003621-15: A Phase II study of a Combination of Eribulin and capecitabiNe in second line Treatment after the failure of gemcitabine/abraxane first line in advanced pancreatic cancer Studio di Fase II di eribulina in combinazione con capecitabina per il trattamento di seconda linea in pazienti affetti da carcinoma pancreatico avanzato dopo fallimento di terapia di prima linea con gemcitabina/abraxane.

Not yet recruiting
2
25
Europe
HALAVEN, Capecitabina accord 150, Capecitabina Accord 500, [-], Solution for infusion, Film-coated tablet, HALAVEN - 0.44MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 2ML 6 FLACONCINI, CAPECITABINA ACCORD - 150 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) - 120 COMPRESSE, CAPECITABINA ACCORD - 500 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) - 120 COMPRESSE
AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA, EISAI srl
advanced pancreatic cancer tumore del pancreas avanzato, advanced pancreatic cancer tumore del pancreas avanzato, Diseases [C] - Cancer [C04]
 
 
2017-004652-35: Second line ERIbulin followed by CApecitabine or the reverse sequence in HER2-negative Metastatic Breast Cancer (MBC) patients: a randomized phase II study – ERICA trial ERIbulina in seconda linea seguita da CApecitabina o sequenza inversa in pazienti con carcinoma mammario metastatico (MBC) HER2-negativo: uno studio randomizzato di fase II – Studio ERICA

Ongoing
2
150
Europe
HALAVEN, Xeloda, [Eribulina], [Capecitabina], Solution for injection, Film-coated tablet, HALAVEN - 0.44MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 2ML 6 FLACONCINI, XELODA - 500 MG 120 COMPRESSE FILMRIVESTITE IN BLISTER USO ORALE
CONSORZIO ONCOTECH, EISAI S.r.l.
HER2-negative Metastatic Breast Cancer Carcinoma mammario metastatico HER2-negativo, Metastatic Breast Tumour Tumore al seno metastatico, Diseases [C] - Cancer [C04]
 
 
ELTOP, UMIN000005219: Japanese A Randomized Phase II Study Comparing Trastuzumab + Capecitabine Combination (HX Therapy) Versus Lapatinib + Capecitabine Combination (LX Therapy) in HER2-Positive Metastatic or Unresectable Locally Advanced Breast Cancer Previously Treated with

Completed
2
110
Japan
Herceptin (trastuzumab) - Roche, capecitabine - Generic mfg., lapatinib - Generic mfg.
GlaxoSmithKline K.K.
HER2-positive metastatic or unresectable locally advanced breast cancer
 
 
2017-003151-34: Clinical trial evaluating the benefit of a post-operative treatment associating radiotherapy + Nivolumab + Ipilimumab versus radiotherapy + Capecitabine for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy. Essai évaluant le bénéfice clinique d’un traitement post-opératoire associant radiothérapie + Nivolumab + Ipilimumab versus radiothérapie + Capécitabine chez des patientes atteintes d’un cancer du sein triple négatif et présentant une maladie résiduelle après chimiothérapie néoadjuvante.

Not yet recruiting
2
98
Europe
Nivolumab, Ipilimumab, Capecitabine, Solution for infusion, Solution for injection, Film-coated tablet, Opdivo, Yervoy, Capecitabine
Centre Léon Bérard, Bristol-Myers Squibb
Triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy Cancer du sein triple négatif et présentant une maladie résiduelle après chimiothérapie néoadjuvante, Breast cancer Cancer du sein, Diseases [C] - Cancer [C04]
 
 
2018-004758-39: STUDY OF CAPECITABINE PLUS CONCOMITANT RADIATION THERAPY FOLLOWED BY DURVALUMAB AS PREOPERATIVE TREATMENT IN PATIENTS WITH RECTAL CANCER STUDIO CLINICO DEL TRATTAMENTO PREOPERATORIO CON CAPECITABINA E RADIOTERAPIA SEGUITE DA DURVALUMAB IN PAZIENTI CON TUMORE DEL RETTO

Not yet recruiting
2
60
Europe
Durvalumab, [MEDI4736], Concentrate for solution for infusion
AZIENDA UNITÀ SANITARIA LOCALE DELLA ROMAGNA, AstraZeneca S.p.A., AUSL della Romagna
Locally advanced (T3-4 N0-1) rectal cancer. Carcinoma del retto localmente avanzato, T3-4 e N0-1., Rectal cancer Tumore del retto, Diseases [C] - Cancer [C04]
 
 
2018-003896-37: n/a

Not yet recruiting
2
125
Europe
tesetaxel, Xeloda, DJ-927, Capsule, hard, Film-coated tablet, Xeloda
Odonate Therapeutics, Inc., Odonate Therapeutics, Inc.
breast cancer cáncer de mama, breast cancer cáncer de mama, Diseases [C] - Cancer [C04]
 
 
2019-002400-40: Prospective study in patients with cancer of the colon or rectum with liver metastasis, of the efficacy and toxicity of standard therapy (chemotherapy + targeted therapy) combined with immunotherapy and internal radiotherapy targeting the liver Etude prospective chez des patients atteints d'un cancer du colon ou du rectum avec des métastase au foie, de l'efficacité et de la toxicité d'une thérapie standard (chimiothérapie + thérapie ciblée) associée à une immunothérapie et une radiothérapie interne ciblant le foie

Not yet recruiting
2
52
Europe
atezolizumab, RO5541267, Solution for infusion, Concentrate for solution for infusion, CAPÉCITABINE MYLAN, OXALIPLATINE HOSPIRA, Avastin, Tecentriq
Fédération Francophone de Cancérologie Digestive, ROCHE, Boston Scientific
MICROSATELLITE STABLE (MSS) COLORECTAL CANCER WITH LIVER-DOMINANT METASTASIS, METASTATIC COLORECTAL CANCER WITH SPECIFIC MOLECULAR PROFIL (MSS) AND LIVER-DOMINANT METASTASIS, Diseases [C] - Cancer [C04]
 
 
2020-002344-23: Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin in metastatic colorectal cancer carcinomaAn open-label phase II Régorafenib en association avec une polychimiothérapie métronomique à base de cyclophosphamide, capecitabine et aspirine à faible dose dans le traitement des cancers colorectaux métastatiques. Etude de phase II

Ongoing
2
49
Europe
Régorafenib, Cyclophosphamide métronomique, Capécitabine, Aspirine, Coated tablet, Tablet, Powder for oral solution, STIVARGA, Cyclophosphamide métronomique, Xeloda, Kardégic
CHU de Besançon, BAYER
Metastatic colorectal cancer Cancer colorectal métastatique, Metastatic colorectal cancer Cancer colorectal métastatique, Diseases [C] - Cancer [C04]
 
 
RELATIVITY-060, NCT03662659 / 2018-001069-18: An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Completed
2
274
Europe, Canada, US, RoW
BMS-986213, Nivolumab, Opdivo, BMS-936558, XELOX, FOLFOX, SOX
Bristol-Myers Squibb
Gastric Cancer, Cancer of the Stomach, Esophagogastric Junction
08/20
01/24
2019-001471-36: Prime RT - using chemotherapy and radiotherapy to charge the immune system making immunotherapies more effective in boosting anti-cancer immune responses in rectal cancer

Not yet recruiting
2
54
Europe
Durvalumab, Oxaliplatin, Fluorouracil, Folinic Acid, capecitabine, Concentrate for solution for infusion, Solution for injection/infusion, Film-coated tablet, Durvalumab
NHS Greater Glasgow and Clyde, The University of Glasgow, , AstraZeneca
Rectal Cancer., Cancer of the lower end of the large bowel., Diseases [C] - Cancer [C04]
 
 
2019-000569-19: A Phase 2 study of lenvatinib (E7080/MK-7902) with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that has progressed after platinum therapy and immunotherapy (LEAP-009)

Not yet recruiting
2
400
Europe, RoW
PEMBROLIZUMAB, KEYTRUDA (pembrolizumab, MK-3475), Lenvatinib, Docetaxel EVER Valinject, Docetaxel Amneal, Docetaxel Aurobindo, Capecitabine Accord, Paclitaxel EVER Pharma, Erbitux (Cetuximab), Docetaxel, Capecitabine, Paclitaxel, Cetuximab, MK-3475, E7080/MK-7902, Solution for infusion, Capsule, hard, Concentrate for solution for infusion, Film-coated tablet, KEYTRUDA (pembrolizumab, MK-3475), Docetaxel EVER Valinject, Docetaxel Amneal, Docetaxel Aurobindo, Capecitabine Accord, Paclitaxel EVER Pharma, Erbitux (Cetuximab), Docetaxel, Capecitabine, Paclitaxel, Cetuximab
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme LLC, Eisai Limited, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Recurrent/metastatic head and neck squamous cell carcinoma, Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) which has progressed after treatment with both platinum therapy and most recently immunotherapy, Diseases [C] - Cancer [C04]
 
 
CA209-8M4, NCT03921684: Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients

Recruiting
2
29
RoW
Capecitabine, Xeloda, Radiation therapy, mFOLFOX6, Nivolumab, Opdivo
Baruch Brenner, Bristol-Myers Squibb
Rectal Cancer
04/21
10/25
ChiCTR1900023710: Toripalimab combined with capecitabine for locally persistent nasopharyngeal carcinoma after radical chemoradiotherapy: a prospective, single-arm, phase II trial

Not yet recruiting
2
23
China
Toripalimab combined with capecitabine
Department of Nasopharyngeal Carcinoma, Cancer Center, Sun Yat-sen University ; Sun Yat-sen University Cancer Center, Junshi Bioscieces biopharmaceutical company presents six courses of Toripalimab for each patient.
Nasopharyngeal Carcinoma
 
 
2020-004636-25: Incidence of cardiovascular events in patients with esophageal/stomach or colorectal cancer treated by trifluridine/tipiracil +/- oxaliplatin after an episode of cardiac angina-related thoracic pain in the adjuvant or metastatic setting.

Not yet recruiting
2
49
Europe
Lonsurf, oxaliplatin, Tablet, Solution for infusion, Lonsurf, oxaliplatin
GERCOR, Servier
colorectal or oesogastric adenocarcinoma, colorectal or oesogastric adenocarcinoma, Diseases [C] - Cancer [C04]
 
 
TBCRC049, NCT03501979: Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Active, not recruiting
2
17
US
Tucatinib, ONT-380, Trastuzumab, Capecitabine
University of Alabama at Birmingham, Translational Breast Cancer Research Consortium, Johns Hopkins University, Seagen Inc., University of Michigan, Georgetown University, University of California, San Francisco, University of Chicago, Indiana University, University of Washington, University of Texas
Metastatic Breast Cancer, Leptomeningeal Disease
07/21
07/24
2021-001181-38: Study on the treatment of patients with gastroesophageal cancer with chemotherapy and immunotherapy based on a non-functioning DNA mismatch repair mechanism in the tumour cells Onderzoek naar de behandeling van patiënten met maag-/slokdarmkanker met chemotherapie en immunotherapie op basis van een niet werkend DNA mismatch herstel mechanisme in de tumorcellen

Not yet recruiting
2
25
Europe
Retifanlimab, INCMGA00012, Solution for infusion
Academic Medical Center, Incyte
Gastroesophageal cancer Oesophagus- en maagcarcinoom, Gastroesophageal cancer Slokdarm- en maagkanker, Diseases [C] - Cancer [C04]
 
 
NCT04262804: A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Active, not recruiting
2
123
RoW
Margetuximab, Trastuzumab, Chosen Chemotherapy (Capecitabine), Chosen Chemotherapy (Vinorelbine ), Chosen Chemotherapy (Gemcitabine )
Zai Lab (Shanghai) Co., Ltd.
Breast Cancer Metastatic
09/21
12/23
OXEL, NCT03487666: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease

Active, not recruiting
2
45
US
Nivolumab, Opdivo, Capecitabine, Xeloda
Georgetown University, Bristol-Myers Squibb
Triple Negative Breast Cancer
11/21
12/22
2021-001575-16: Selective Internal Radiation Therapy and Capecitabine (chemotherapy) treatment for liver cancer Traitement par Radiothérapie Interne Sélective et Capecitabine (chimiothérapie) dans le cancer du foie

Not yet recruiting
2
62
Europe
CAPECITABINE ACCORD, THERASPHERE, Coated tablet, Radiopharmaceutical precursor, solution, CAPECITABINE ACCORD, THERASPHERE
Centre Régional de lutte contre le Cancer Eugène Marquis, Boston Scientific Corporation, Centre Régional de lutte contre le cancer Eugène Marquis
Patients having operable intrahepatic cholangiocarcinoma Patients présentant un cholangiocarcinome intra-hépatique résécable, Biliary tract cancer Cancer des voies biliaires, Diseases [C] - Cancer [C04]
 
 
NCT01191697: CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Active, not recruiting
2
37
US
bevacizumab, Avastin, trastuzumab, Herceptin, oxaliplatin, capecitabine, xeloda
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Genentech, Inc.
Esophageal Cancer, Gastric Cancer
12/21
07/24
NCT02555358: Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Clinical Study

Completed
2
300
RoW
docetaxel,0xaliplatin,capecitabine, AISU,AIHENG,AIBIN, oxaliplatin,capecitabine, AIHENG,AIBIN
Qun Zhao, Jiangsu HengRui Medicine Co., Ltd.
Gastric Cancer
12/21
06/22
PANDA, NCT03448835 / 2017-003854-17: Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer

Recruiting
2
20
Europe
Atezolizumab, MPDL3280A, Capecitabine, L01BC06, Oxaliplatin, L01XA03, Docetaxel, L01CD02
The Netherlands Cancer Institute, Hoffmann-La Roche
Stomach Cancer, Gastro Esophageal Junction Cancer
01/22
01/22
2021-000507-20: Study to assess the effect of intensive vs standard adjuvant chemotherapy in localised colon cancer with circulating tumor DNA. Estudio para evaluar el efecto de la quimioterapia adyuvante intensiva frente a la estándar en el cáncer de colon localizado con ADN tumoral circulante.

Not yet recruiting
2
164
Europe
Concentrate for solution for infusion, Powder and solution for solution for injection, Solution for injection/infusion, Film-coated tablet, Irinotecan, OXALIPLATIN, Calcium folinate, FLUORURACIL, Capecitabine
Instituto de Investigación Sanitaria INCLIVA, Instituto de Salud Carlos III
Localised Colon Cancer (stage II-III) Cáncer Colorrectal Localizado (estadio II-III), Colon Cancer (stage II-III) Cáncer Colorrectal (estadio II-III), Diseases [C] - Cancer [C04]
 
 
2021-002389-41: A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer Eine Phase-II-Studie zur Immuntherapie mit Durvalumab und Tremelimumab in Kombination mit Capecitabin oder ohne Capecitabin in der ADJUvanten Situation bei Gallengangskrebs

Ongoing
2
40
Europe
Durvalumab, Tremelimumab, Capecitabine, Solution for infusion, Film-coated tablet, IMFINZI
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, AstraZeneca GmbH
biliary tract cancer, biliary tract cancer, Diseases [C] - Cancer [C04]
 
 
NCT00962520: Tarceva With Chemoradiation and Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Checkmark ASCO-GI 2013
Jan 2013 - Jan 2013: ASCO-GI 2013
Checkmark P2 data
Nov 2011 - Nov 2011: P2 data
Active, not recruiting
2
40
US
Erlotinib, Tarceva, capecitabine, Xeloda, Radiation Therapy, gemcitabine, Gemzar, erlotinib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Genentech, Inc.
Pancreatic Cancer
04/22
04/23
RIGHT Choice, NCT03839823: Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Completed
2
223
RoW
Docetaxel / Capecitabine, Combination chemotherapy group., The chemotherapy regimen will be decided by the treating physician., Capecitabine / Vinorelbine, Paclitaxel / Gemcitabine, Ribociclib, Endocrine treatment arm:, NSAI + goserelin+ ribociclib, Letrozole OR Anastrozole, Goserelin
Novartis Pharmaceuticals
Breast Cancer
04/22
05/23
NCT04159142: Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Recruiting
2
414
RoW
Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Capecitabine
Hebei Medical University Fourth Hospital, Beijing 302 Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.
Triple Negative Breast Cancer, Nab-paclitaxel
06/22
09/22
2022-000273-81: Randomised phase II study evaluating trifluridine/tipiracil plus oxaliplatin versus FOLFOX in patients with gastric, oesophagus or gastroesophageal junction adenocarcinoma locally advanced, recurrent or metastatic, ineligible for triplet chemotherapy

Not yet recruiting
2
118
Europe
LONSURF, ELVORINE, Coated tablet, Solution for infusion, Capsule, LONSURF, ELOXATINE, FOLINATE DE CALCIUM, 5-Fluorouracil, capecitabine, ELVORINE
UNICANCER, Laboratoire SERVIER
Patients with gastric, oesophagus or gastroesophageal junction adenocarcinoma locally advanced, recurrent or metastatic, ineligible for triplet chemotherapy., Oxaliplatin in combination with trifluridine/tipiracil or 5-fluorouracile in frail patients with advanced, recurrent or metastatic gastric, oesophageal or gastroesophageal junction cancer, Diseases [C] - Cancer [C04]
 
 
AK112-206, NCT05382442: A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

Recruiting
2
104
RoW
AK112, AK117, Oxaliplatin, Capecitabine, Irinotecan, Leucovorin, 5-fluorouracil
Akeso
Metastatic Colorectal Cancer
12/24
12/26
2022-000776-19: Master Protocol of Dato-DXd as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours Protocolo Maestro de Dato-DXd en Monoterapia y en Combinación con Agentes Antineoplásicos en Pacientes con Tumores Sólidos en Estadio Avanzado o Metastásico

Not yet recruiting
2
670
Europe
AZD5305, Durvalumab, Datopotamab deruxtecan, Capecitabine, Flourouracil (5-FU), Bevacizumab, Carboplatin, leucovorin, Nivolumab, AZD5305, MEDI4736, DS-1062a, Film-coated tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Solution for injection, MVASI, Prednisolone
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Various Advanced/Metastatic solid tumour types- Endometrial Cancer - Gastric Cancer - Ovarian Cancer- Metastatic castration-resistant prostate cancer- Colorectal cancer Varios tipos de tumores sólidos avanzados/metastásicos- Cáncer endometrial- Cáncer gástrico- Cáncer de ovario- Cáncer de próstata metastásico resistente a la castración- Cáncer colorrectal, Metastatic Cancer, Multiple cancers Cáncer metastásico, Múltiples cánceres, Diseases [C] - Cancer [C04]
 
 
PANDORA, NCT04083365: Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer

Recruiting
2
100
Europe
Capecitabine, Radiotherapy, Durvalumab
AUSL Romagna Rimini, AstraZeneca, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
RECTAL CANCER
11/22
08/25
SAFIR02_Breast, NCT02299999: - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active, not recruiting
2
1460
Europe
AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, ARRY-142866, Vandetanib, CAPRELSA, Bicalutamide, Casodex, Olaparib, Lynparza, Anthracyclines, Doxorubicin, Epirubicin, liposomal doxorubicin, Taxanes, paclitaxel, docetaxel, cyclophosphamide, Novatrex, Imeth, DNA intercalators, capecitabine, 5-FU, gemcitabine, Methotrexate, vinca alkaloids, vinorelbine, vinblastine, vincristine, Platinum based chemotherapies, Platinum, carboplatin, cisplatin, Bevacizumab, Avastin, Mitomycin C, Ametycine, Eribulin, Halaven, MEDI4736
UNICANCER, Fondation ARC, AstraZeneca
Metastatic Breast Cancer
12/22
12/24
ALTER-G-001, NCT05262335: Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis

Recruiting
2
116
RoW
Anlotinib + Oxaliplatin + Capecitabine, Anlotinib + Cisplatin + Paclitaxel/ Docetaxel, Anlotinib + Standard first-line chemotherapy
Ruijin Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gastrointestinal Tumors
12/23
12/24
NCT05545436: Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer

Recruiting
2
34
RoW
Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine ), Camrelizumab + SOX / XELOX
Third Affiliated Hospital, Sun Yat-Sen University, Jiangsu Hengrui Pharmaceutical Co., Ltd.
Locally Advanced Gastric Cancer
12/22
06/23
NCT01494662: HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Hourglass Jan 2022 - Jun 2022 : Data from trial in combination with neratinib for HER2-positive breast cancer with brain metastases
Hourglass Jul 2021 - Dec 2021 : Data from cohort 4 of P2 trial in combination with kadcyla for HER2-positive breast cancer
Checkmark Pooled data from NALA, NEfERT-T and TBCRC 022 trials for HER2-positive breast cancer at SABCS 2019
Dec 2019 - Dec 2019: Pooled data from NALA, NEfERT-T and TBCRC 022 trials for HER2-positive breast cancer at SABCS 2019
Checkmark In HER2+ metastatic breast cancer with brain metastases
More
Active, not recruiting
2
140
US
HKI-272, Neratinib, Surgical Resection, Biopsy, Capecitabine, Xeloda, Ado-Trastuzumab Emtansine, T-DM1
Dana-Farber Cancer Institute, Translational Breast Cancer Research Consortium, Puma Biotechnology, Inc.
Breast Cancer
02/23
12/24
KeyLargo, NCT03342937: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer

Completed
2
36
US
Oxaliplatin+Capecitabine+Pembrolizumab
Duke University, Merck Sharp & Dohme LLC
Gastric Cancer, Esophagus Cancer
02/23
02/23
NCT04894123: Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients

Terminated
2
1
Europe
Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, Eloxatin
GERCOR - Multidisciplinary Oncology Cooperative Group, Servier
Colorectal Adenocarcinoma, Oesogastric
02/23
02/23
NCT04908813: Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer

Active, not recruiting
2
150
RoW
HLX22, Placebo, Trastuzumab, Oxaliplatin, Capecitabine
Shanghai Henlius Biotech
Gastric Cancer
12/24
12/25
NCT04661150: A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

Active, not recruiting
2
41
RoW
Atezolizumab, Tecentriq, Trastuzumab, Herceptin, Capecitabine, Oxaliplatin
Hoffmann-La Roche
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
05/23
08/26
NCT04443348: Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Recruiting
2
120
US
Radiation Therapy Boost, Pembrolizumab, Keytruda®., Paclitaxel, Taxol, Carboplatin, Paraplatin, Cyclophosphamide, Cytophosphane, Doxorubicin, Adriamycin, Capecitabine
Laura M. Spring, MD, Merck Sharp & Dohme LLC, Breast Cancer Research Foundation, Translational Breast Cancer Research Consortium
Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
06/24
12/24
REPROGRAM-01, NCT04534218: Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer

Completed
2
49
Europe
Regorafenib, Stivarga, Cyclophosphamide, Endoxan, Capecitabine, Xeloda, Aspirin, Kardegic
Centre Hospitalier Universitaire de Besancon, Bayer
Colo-rectal Cancer, Metastatic Cancer
12/23
12/23
MK-7119-001, NCT04721977: A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma

Active, not recruiting
2
66
Japan, RoW
Tucatinib, MK-7119, Tukysa, Trastuzumab, Herceptin, Herceptin Hylecta, Capecitabine, Xeloda
Pfizer
Breast Cancer
07/23
12/28
2018-000406-36: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study (VESTIGE)

Not yet recruiting
2
240
Europe
nivolumab, ipilimumab, CISPLATIN, CAPECITABINE, Fluorouracil, EPIRUBICIN, Oxaliplatin, LEUCOVORIN, Docetaxel, L01XC11, Concentrate for solution for infusion, Film-coated tablet, Opdivo, Yervoy
European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for the Research and Treatment of Cancer, BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
Gastric, lower esophageal or GE-junction adenocarcinoma, Stomach cancer and cancer of the lower part of the esophageus, Diseases [C] - Cancer [C04]
 
 
NCT05546411: A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

Terminated
2
8
US
mFOLFIRINOX, 5-Fluorouracil (5-FU), Adrucil, Oxaliplatin, Eloxatin, Irinotecan, Camptosar, Camptothecin-11, CPT-1, Leucovorin, Calcium Leucovorin, Citrovorum Factor, Folinic Acid, NIS793, Chemoradiation, Surgery
Kimberly Perez, MD, Novartis
Pancreatic Cancer, Resectable Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma
08/23
10/23
N-PRC, NCT05576480: SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer

Not yet recruiting
2
55
NA
Short-course radiotherapy, Penpulimab, PD-1 monoclonal antibody, CAPEOX, Capecitabine and oxaliplatin, TME surgery
Ruijin Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Rectal Cancer, Locally Advanced
10/23
12/26
NCT04933227: A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Terminated
2
29
RoW
Atezolizumab, Tecentriq, Tiragolumab, Oxaliplatin, Capecitabine
Hoffmann-La Roche
Stomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
11/23
11/23
OPRA, NCT02008656: Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

Active, not recruiting
2
358
US
Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin, Capecitabine (Xeloda®), intensity modulated radiotherapy (IMRT), Quality of Life Questionnaires, DRE-Endoscopy
Memorial Sloan Kettering Cancer Center, Colon and Rectal Surgery Inc., The Cleveland Clinic, John Muir Health, Oregon Health and Science University, St. Joseph Hospital of Orange, University of California, Irvine, University of California, San Francisco, University of Chicago, University of South Florida, University of Vermont, University of Washington, Medstar Health Research Institute, Washington University School of Medicine, Creighton University Medical Center, The Methodist Hospital Research Institute, University of Rochester, University of Virginia, St. Paul's Hospital, St. Joseph, Florida, Cleveland Clinic Florida, University of Colorado, Denver, University of Michigan
Rectal Cancer
11/24
11/24
NCT06155383: Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Recruiting
2
90
RoW
Capecitabine, oxaliplatin, Disitamab Vedotin, RC48, Toripalimab, JS001
RemeGen Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
01/25
12/27
PATHFINDER, NCT04464174: Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer

Completed
2
54
Europe
Ipatasertib, GDC-0068, Capecitabine, Xeloda, Eribulin, Halaven, Carboplatin, Paraplatin, Gemcitabine, Gemzar
MedSIR, Hoffmann-La Roche
Triple Negative Breast Cancer
11/23
11/23
NCT05068206: A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx

Recruiting
2
120
RoW
AK105 injection, Anlotinib hydrochloride capsule, CapeOX, Bevacizumab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Unresectable Metastatic Colorectal Cancer
12/23
06/24
NCT06256328: A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Recruiting
2
210
Japan, RoW
ONO-4578, Oxaliplatin, Capecitabine, S-1, Tegafur-gimeracil-oteracil potassium, Nivolumab, Opdivo, Placebo
Ono Pharmaceutical Co. Ltd
Gastric Cancer
11/25
12/27
NCT05246982: HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer

Recruiting
2
40
RoW
HLX07+HLX10+oxaliplatin+capecitabine, HLX07
Shanghai Henlius Biotech
Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
12/23
03/24
MyTACTIC, NCT04632992: A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Completed
2
252
US
Entrectinib, Rozlytrek™, RG6268, RO7102122, Inavolisib, GDC-0077, RG6114, RO7113755, Alectinib, Alecensa®, RG7853, RO5424802, Ipatasertib, GDC-0068, RG7440, RO5532961, Atezolizumab, Tecentriq®, RG7446, RO5541267, Trastuzumab Emtansine, Kadcyla®, RG3502, RO5304020, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, PHESGO™, PH FDC SC, Fixed dose combination of trastuzumab and pertuzumab administered subcutaneously, RG6264, RO7198574, Tucatinib, Tukysa™, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, RG6058, RO7092284, MTIG7192A, Pralsetinib, GAVRETO™, RG6396, RO7499790
Genentech, Inc.
Advanced Unresectable or Metastatic Solid Malignancy
12/23
02/24
NCT05009069: A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Active, not recruiting
2
58
RoW
Radiotherapy, Capecitabine, Fluorouracil, Atezolizumab, Tiragolumab
Hoffmann-La Roche
Rectal Neoplasms, Rectal Cancer
11/23
10/26
NCT06247956: Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer

Recruiting
2
120
RoW
SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection, Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma
02/25
08/25
NCT05336721: A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Recruiting
2
38
RoW
Chiauranib, capecitabine
Chipscreen Biosciences, Ltd.
Triple-negative Breast Cancer
03/24
08/24
REVISE, NCT06242418: ctDNA in Adjuvant Chemotherapy of Stage III Colon Cancer ( Trial)

Recruiting
2
60
RoW
FOLFOXIRI, XELOX
West China Hospital, GeneCast Biotechnology Co., Ltd.
Colon Cancer
12/25
12/26
NCT05799820: QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

Recruiting
2
60
RoW
QL1706, Bevacizumab, Oxaliplatin injection, Capecitabine
Qilu Pharmaceutical Co., Ltd.
Colorectal Carcinoma
03/24
09/25
CVL009-2002, NCT06374888: Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

Not yet recruiting
2
28
NA
Neratinib maleate in combination with capecitabine
Convalife (Shanghai) Co., Ltd.
Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis
09/26
07/27
Pan-MSI-ACSE, NCT06333314: Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

Not yet recruiting
2
120
Europe
Dostarlimab, Chemotherapy
UNICANCER, National Cancer Institute, France, GlaxoSmithKline
Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma
10/28
09/30
NCT05648006: First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer

Terminated
2
7
RoW
OH2, Capecitabine, Bevacizumab
Binhui Biopharmaceutical Co., Ltd.
Advanced Colorectal Carcinoma
04/24
04/24
BL-M07D1-206, NCT06423885: A Study of BL-M07D1+PD-1 Monoclonal Antibody and BL-M07D1+PD-1 Monoclonal Antibody+Capecitabine in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

Not yet recruiting
2
86
RoW
BL-M07D1, PD-1 monoclonal antibody, Capecitabine
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
06/26
06/26
NCT06458413: Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer

Recruiting
2
40
RoW
Utidelone Capsule Plus Capecitabine
Min Yan, MD, Beijing Biostar Pharmaceuticals Co., Ltd.
Breast Cancer Recurrent
06/25
12/25
TRIFLUOX-DP, NCT06245356: Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

Not yet recruiting
2
73
NA
Lonsurf, Oxaliplatin, Panitumumab, Bevacizumab, Trastuzumab, Nivolumab
UNICANCER, Servier
Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency
06/26
06/28
CHINOREC, NCT04124601 / 2019-003865-17: Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer

Completed
2
80
Europe
Chemoradiotherapy, Radiochemotherapy, Chemoradiation, Ipilimumab, Yervoy®, Nivolumab, Opdivo®
Johannes Laengle, MD, PhD, Bristol-Myers Squibb
Rectal Cancer
03/24
03/24
NCT05980689: Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer

Recruiting
2
33
RoW
AK104, Cadonilimab, Capecitabine, Neoadjuvant Radiotherapy
Sun Yat-sen University, Akeso, Haplox Biotechnology Co., Ltd.
Locally Advanced Rectal Cancer
06/24
01/25
NCT06430827: Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma

Not yet recruiting
2
20
RoW
irinotecan hydrochloride liposome injection, duoenyi, Capecitabine, Kapeitabin
Ba Yi, CSPC Ouyi Pharmaceutical Co., Ltd.
Biliary Tract Carcinoma
12/24
12/25
QLS31905-202, NCT06446388: Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Not yet recruiting
2
360
RoW
QLS31905, Oxaliplatin, Capecitabine, Gemcitabine, Cisplatin, QL1706, Chemotherapy drug
Qilu Pharmaceutical Co., Ltd.
Advanced Solid Tumor
06/26
12/27
PEGASUS, NCT04259944: Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the Trial

Active, not recruiting
2
140
Europe
CAPOX, Capecitabine, FOLFIRI
IFOM ETS - The AIRC Institute of Molecular Oncology, Guardant Health, Inc.
Colon Cancer
07/24
10/24
NCT05300269: SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer

Recruiting
2
73
RoW
SHR-1701；Capecitabine；Oxaliplatin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Locally Advanced Rectal Cancer
07/24
10/26
LyRICX, NCT03764553: Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer

Recruiting
2
310
Europe
Liposomal Irinotecan, Carboplatin, Capecitabine, Xeloda, Oxaliplatin, 5-fluorouracil, Leucovorin
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Servier
Esophageal Cancer
08/24
08/24
NCT03984578: Window of Opportunity Study in Colorectal Cancer

Recruiting
2
50
RoW
CAPEOX, Pembrolizumab, Keytruda, Capecitabine/ 5-FU, CAPEOX/Pembrolizumab, Pembrolizumab alone, Surgical resection
National Cancer Centre, Singapore, Merck Sharp & Dohme LLC
Colorectal Cancer
08/24
08/24
LEAP-009, NCT04428151: Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/)

Recruiting
2
400
Europe, Canada, US, RoW
Lenvatinib, LENVIMA®, MK-7902, E7080, Pembrolizumab, KEYTRUDA®, MK-3475, SCH 900475, Docetaxel, TAXOTERE®, Capecitabine, Xeloda®, Paclitaxel, Taxol, Cetuximab, ERBITUX®
Merck Sharp & Dohme LLC, Eisai Inc.
Squamous Cell Carcinoma of Head and Neck
07/25
02/27
ALTER-HN005, NCT05807880: Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma

Not yet recruiting
2
110
NA
The combination treatment of anlotinib, penpulimab and capecitabine.
Sun Yat-sen University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nasopharyngeal Neoplasms
10/24
10/25
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Recruiting
2
238
RoW
MRG003, Capecitabine tablets, Docetaxel injection
Shanghai Miracogen Inc.
Recurrent or Metastatic Nasopharyngeal Carcinoma
10/24
02/25
EXPLORING, NCT05494060: XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

Recruiting
2
80
RoW
Anlotinib hydrochloride capsule, Penpulimab Injection, AK-105, XELOX, Capecitabine and Oxaliplatin
The First Affiliated Hospital with Nanjing Medical University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Carcinoma, Gastrointestinal Diseases, Stomach Cancer, Gastroesophageal-junction Cancer, Digestive System Diseases, Gastric Cancer, Gastrointestinal Neoplasms
12/24
02/27
DUREC, NCT04293419: Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer

Recruiting
2
58
Europe
Durvalumab (MEDI4736)
Grupo Espanol Multidisciplinario del Cancer Digestivo, AstraZeneca, Vall d'Hebron Institute of Oncology (VHIO)
Rectal Cancer
12/24
03/25
NCT02955940: An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Active, not recruiting
2
10
Europe, US
Ruxolitinib, INCB018424, Jakafi®, Capecitabine, Xeloda®, Regorafenib, Stivarga®
Incyte Corporation
Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer
12/24
12/24
NCT05420779: A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations

Recruiting
2
125
RoW
TSL-1502 capsules(low dose), TSL-1502 capsules(high dose), Investigator's choice of chemotherapy
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
Breast Cancer Metastatic
12/24
06/26
PLATFORM, NCT02678182: Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

Recruiting
2
924
Europe
Capecitabine, MEDI4736, Trastuzumab, Rucaparib, Ramucirumab
Royal Marsden NHS Foundation Trust, MedImmune LLC, Clovis Oncology, Inc., Eli Lilly and Company, AstraZeneca
Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction, Adenocarcinoma of the Stomach
03/25
06/27
TROPION-PanTumor03, NCT05489211 / 2022-000776-19: Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours

Calendar Jan 2024 - Dec 2024: Data from TROPION-PanTumor03 trial for advanced solid tumors
Recruiting
2
531
Europe, Canada, Japan, US, RoW
Datopotamab deruxtecan (Dato-DXd), DS-1062a, Saruparib, AZD5305, Durvalumab, MEDI4736, IMFINZI, Capecitabine, Xeloda, 5-Fluorouracil, Adrucil, Volrustomig, MEDI5752, Carboplatin, Paraplatin, Leucovorin LV, Folinic acid, Bevacizumab, Avastin, Rilvegostomig, AZD2936, Prednisone/ prednisolone, Prednisolone
AstraZeneca, Daiichi Sankyo
Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
08/26
08/26
AuspiCiOus, NCT05177133: Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer

Recruiting
2
25
Europe
Capecitabine, Xeloda, Oxaliplatin, Oxaliplatin Accord, Retifanlimab, INCMGA00012
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Incyte Corporation
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
05/25
11/29
DisTinGuish, NCT04363801: A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Hourglass Oct 2023 - Mar 2024 : Q4'23/Q1'24 - Initial ORR data from DisTinGuish trial for 2L gastric cancer
Oct 2023 - Dec 2023: Initial data from part C of DisTinGuish trial in combination with tislelizumab for 1L gastric cancer
Checkmark Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Nov 2022 - Nov 2022: Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Checkmark ORR, PFS and OS data from DisTinGuish trial in combination with tislelizumab for gastroesophageal junction cancer or gastric cancer
More
Active, not recruiting
2
232
Europe, US, RoW
DKN-01 300mg, DKN-01 600mg, DKN-01 400mg, Tislelizumab 200mg, Tislelizumab 400mg, Oxaliplatin, Capecitabine 1000mg/ m2 BID, Xeloda, Leucovorin Calcium, Folinic acid, Fluorouracil
Leap Therapeutics, Inc., BeiGene
Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
06/25
12/25
PRIME-RT, NCT04621370: A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer

Not yet recruiting
2
48
NA
Durvalumab, MEDI 4736, FOLFOX, mFOLFOX6, Short Course Radiotherapy (Arm A), Long course chemoradiation (Arm B), Capecitabine
Liz-Anne Lewsley, University of Glasgow, AstraZeneca, NHS Greater Glasgow and Clyde
Rectal Cancer, Rectal Adenocarcinoma, Rectal Neoplasms
06/25
12/25
Cornerstone001, NCT05163223: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

Terminated
2
10
US, RoW
AST-301(pNGVL3-hICD), AST-301, rhuGM-CSF, Leukine, Sargramostim, Placebo, Normal Saline, Pembrolizumab, Keytruda, Capecitabine, Xeloda
Aston Sci. Inc.
Breast Cancer
05/24
05/24
CA209-8TT, NCT03899155 / 2018-004362-34: Pan Tumor Rollover Study

Recruiting
2
1500
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558-01, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, BMS-986016-01, Nivolumab + Relatlimab, BMS-986213, Capecitabine, Bevacizumab, Temozolomide, Rucaparib, Daratumumab, Regorafinib, Leucovorin, Fluorouracil, Oxaliplatin, Enzalutamide, Sunitinib, Pemetrexed, Pembrolizumab
Bristol-Myers Squibb, Exelixis, Novartis, Clovis Oncology, Inc., Janssen Pharmaceuticals
Cancer
08/29
08/29
DESTINY-Gastric03, NCT04379596: Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer

Jul 2023 - Dec 2023: Data from DESTINY-Gastric03 trial for gastric cancer
Checkmark Presentation of data from DESTINY-Gastric03 study in HER2-overexpressing gastric cancer at ESMO 2020
Jul 2020 - Jul 2020: Presentation of data from DESTINY-Gastric03 study in HER2-overexpressing gastric cancer at ESMO 2020
Recruiting
2
413
Europe, Canada, Japan, US, RoW
Fluorouracil (5-FU), Capecitabine, Durvalumab, MEDI4736, Oxaliplatin, Trastuzumab, Trastuzumab deruxtecan, DS-8201a, Cisplatin, Pembrolizumab, Volrustomig, MEDI5752, Rilvegostomig, AZD2936
AstraZeneca, Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo
Gastric Cancer
07/26
07/26
GEMINI-Gastric, NCT05702229 / 2022-002840-29: Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
2
240
Europe, Japan, US, RoW
Rilvegostomig, Volrustomig, FOLFOX, XELOX, AZD7789, AZD0901, 5-Fluorouracil, Capecitabine
AstraZeneca, AstraZeneca AB
Gastric Cancer
09/25
03/26
ERASE-CRC, NCT05062889: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Recruiting
2
477
Europe
5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5FU, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule, Oxaliplatin FOLFOX and FOLFOXIRI schedule, Oxa, Oxaliplatin CAPOX schedule, L-Leucovorin, Lederfolin, Capecitabine, Irinotecan, Trifluridine/Tipiracil, FTD/TPI, Trastuzumab, Tucatinib
Gruppo Oncologico del Nord-Ovest, Servier, Foundation Medicine, Seagen Inc.
Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer, RAS Wild-type Colon Cancer
10/25
12/27
NCT06016387: Tucatinib With Brain and/or Spinal XRT in Patients With HER2+ Metastatic Breast Cancer and LMD

Recruiting
2
30
Canada
Tucatinib 150 MG, Tukysa, Trastuzumab, Capecitabine, Brain & Spinal Radiation, Brain & Spinal XRT
Sunnybrook Health Sciences Centre, Seagen Inc., Biocon Biologics
HER2-positive Breast Cancer, LMD
10/25
10/28
ZWI-ZW25-201, NCT03929666: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Active, not recruiting
2
74
Canada, US, RoW
ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine
Jazz Pharmaceuticals
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
11/25
10/26
NCT03396926: Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

Completed
2
44
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Capecitabine, Ro 09-1978/000, Xeloda, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
University of California, San Francisco, Merck Sharp & Dohme LLC
Microsatellite Stable, Mismatch Repair Protein Proficient, Stage III Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
01/24
01/24
PaTK02, NCT02446093: Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Active, not recruiting
2
54
US, RoW
Aglatimagene besadenovec, CAN-2409, AdV-tk, Chemoradiation, Stereotactic body radiation therapy, Surgery
Candel Therapeutics, Inc., Mayo Clinic
Borderline Resectable Pancreatic Adenocarcinoma
12/25
07/26
NCT02688712: ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

Active, not recruiting
2
50
US
LY2157299, Galunisertib, Capecitabine, Xeloda, Fluorouracil, 5-fluorouracil , 5-FU, Adrucil, Efudex, Fluoroplex, Tumor specific mesorectal excision
Providence Health & Services, Eli Lilly and Company
Rectal Adenocarcinoma
12/25
12/25
NCT04753879: Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Recruiting
2
38
US
Nab-paclitaxel, Gemcitabine, Cisplatin, Irinotecan, Capecitabine, Pembrolizumab, Olaparib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC
Metastatic Pancreatic Cancer
12/25
12/29
 

Download Options